Orphan drugs, often referred to as the pharmaceutical underdogs, are medications developed to treat rare diseases that affect a small number of individuals. These conditions, termed orphan diseases, typically lack attention and funding due to their limited prevalence, making them commercially unattractive for large pharmaceutical companies.
The term "orphan" in this context doesn't denote the drugs' efficacy but rather the economic challenge of developing treatments for small patient populations. To incentivize research and development in this crucial area, governments often provide incentives such as extended market exclusivity and tax credits. The significance of orphan drugs lies in their ability to bring hope to individuals facing conditions that might otherwise lack effective treatments. By addressing rare diseases, these drugs contribute to a more inclusive and compassionate healthcare landscape, emphasizing the importance of providing solutions for all, regardless of the rarity of their medical conditions.
Vladlen Slepak
University of Miami Miller School of Medicine, United States
Yong Xiao Wang
Albany Medical College, United States
Consolato M Sergi
Universities of Alberta and Ottawa, Canada
Huiqin Yang
ICON Clinical Research Ltd, United KingdomSubmit your abstract Today
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Antibody proteases as translational tools of the next step generation to be applied for biopharmacy related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India
Title : Cognitivevoice: Novel machine learning model leveraging acoustic features to predict future cognitive decline in Parkinson’s Disease
Aadya Daga, Hamilton High School, United States
Title : Platelet-activating factor-receptor pathway mediates solar radiation-induced extracellular vesicle release in human keratinocytes
Ravi P Sahu, Wright State University, United States